This was originally published by News Medical Life Sciences By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma (MM), the second most common blood cancer in Ireland. The study will be carried out at Beaumont Hospital Dublin and run through...Continue Reading

Dr. Richard E. Stein, Chairman of the Crohn’s & Colitis NZ Charitable Trust, has asked for our support to help share their petition for funding of a desperately needed medication. Their petition asks for funding for a medication called ustekinumab (Stelara) that has been funded in Australia since 2015 and in 37 other countries around the...Continue Reading

DREAM​M 7 – A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belnatamab mafadotin (GSK2857916), Bortezomib, and Dexamethasone Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma Recruitment to start from end of September (Phase III study from GSK) Information and how to...Continue Reading